metformin + glibenclamide (Spey)

Atribet is a fixed-dose combination oral antidiabetic medication containing **metformin hydrochloride** and **glibenclamide** (also known as glyburide). It is marketed by SPEY, a pharmaceutical company active in Southeast Asia and the CIS region, for the management of type 2 diabetes mellitus. Metformin, a biguanide, works by decreasing hepatic glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity by increasing peripheral glucose uptake and utilization. Glibenclamide, a second-generation sulfonylurea, lowers blood glucose by stimulating the release of insulin from the pancreas, a process dependent upon functioning beta cells. The combination is typically used when glycemic control is not achieved with diet, exercise, and single-agent therapy.

Brand names

Atribet

Other names

Metformin/GlibenclamideMetformin/Glyburide